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The levels, regulation and prognostic value of p21 in head and neck squamous cell carcinomas
(HNSCC) has been puzzling for years. Here, we report a new mechanism of regulation of p21
by the mTORC1/4E-BP1 pathway. We find that non-phosphorylated 4E-BP1 interacts with
p21 and induces its degradation. Accordingly, hyper-activation of mTORC1 results in
phosphorylation of 4E-BP1 and stabilization of p21. In HNSCC, p21 levels strongly correlate
with mTORC1 activity but not with p53 status. Finally, clinical data indicate that HNSCC
patients with p21 and phospho-S6-double-positive tumours present a better disease-specific
survival. We conclude that over-activation of the mTORC1/4E-BP1/p21 pathway is a frequent
and clinically relevant alteration in HNSCC.
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P
rogression through the cell cycle in eukaryotic cells is
governed by a suite of cyclin-dependent kinases (CDKs)
and CDK inhibitors. Protein CDKN1A (also known as
p21), encoded by the CDKN1A gene, is a member of the CIP/KIP
family of CDK inhibitors, together with CDKN1B (p27)
and CDKN1C (p57). A main mechanism governing p21
levels is through CDKN1A transcriptional activation by the
tumour-suppressor TP53 (p53). In response to DNA damage
and many other cellular stressors, p21 levels increase in a
p53-dependent manner and contribute to arrest cell proliferation.
P21 also regulates multiple cellular processes, including apoptosis,
differentiation and stem cell quiescence1,2. In addition to
transcriptional upregulation by p53, other mechanisms have
been described that regulate p21 levels2,3. Under normal growth
conditions, p21 is an unstable protein with a relatively short
half-life and several proteins involved in p21 degradation have
been identified2.
The serine/threonine kinase MTOR (mTOR) promotes
anabolic processes and cell growth in response to environmental
cues. This is achieved through two distinct multiprotein
complexes containing mTOR and known as mTORC1 and
mTORC2 (refs 4,5). The kinase activity of mTORC1 is positively
regulated by two families of small GTPases, namely, RHEB and
RRAGs (also known as RAGs)6. Of relevance for our current
work, RHEB is negatively regulated by the GTPase-activating
protein TSC2 (refs 6–8). The mTORC1 complex integrates inputs
from at least four major signals: growth factors, energy status,
oxygen and amino acids. When activated, mTORC1 promotes
protein synthesis mainly by phosphorylating the kinases RPS6KB
(also known as S6K) and the translational regulators EIF4EBP
(also known as 4E-BP)9. Upon phosphorylation, 4E-BP releases
the translation factor EIF4E (eIF4E) allowing it to promote the
translation of a subset of mRNAs characterized by the presence of
a terminal oligopyrimidine (TOP) track in the 50-untranslated
region (TOP mRNAs)9,10.
Head and neck squamous cell carcinoma (HNSCC) is the sixth
leading cancer by incidence worldwide and is one of the most
morbid, mortal and genetically diverse malignancies11. Despite
improvements in treatment protocols, the survival rates remain
disappointingly low. Insight in the molecular processes causing
HNSCC may reveal the knowledge to improve and personalize
treatments. The above-described molecular pathways involving
p21 and mTORC1 are frequently deregulated in HNSCCs, but little
is known about the possible connections between these two
pathways. P21 is aberrantly expressed in the majority of HNSCC
and its expression appears to be unrelated to p53 status12–16. On
the other hand, alterations in the major components of the
mTORC1 pathway are consistently observed in a large fraction of
HNSCC cases17–22. Here, we have focused on the mechanistic
connection between p21 and mTORC1. We dissect a mechanism
that regulates p21 stability through the mTORC1/4E-BP1 pathway
and independently of p53, and we show supportive evidence
indicating that this mechanism is highly prevalent in HNSCC.
Results
Hyperactivation of mTORC1 elevates p21 independently of p53.
We were initially motivated by the idea of studying
mTOR-induced senescence in primary cells. Previous
investigations had found that primary mouse embryo fibroblasts
(MEFs) from knockout mice lacking the mTORC1 inhibitor
TSC2 enter senescence prematurely in association with a
remarkable upregulation of p21 (ref. 23). Cellular senescence is a
tumour-suppressor mechanisms activated in response to multiple
cellular stresses, prominently including oncogenic stimuli24. In
this regard, cellular senescence can be considered a read-out of
oncogenic stress in primary cells. In contrast, the senescence
response is generally absent or impaired in cancer cells.
In agreement with a previous report23, we confirmed that TSC2
depletion in primary MEFs, by infection with TSC2 short hairpin
RNA (shRNA)-encoding lentiviruses, induced a robust senescence
response (Fig. 1a). As expected, TSC2 depletion resulted in
constitutive activation of mTORC1, as indicated by hyper-
phosphorylation of ribosomal protein RPS6 (S6; Fig. 1a). In
addition, and similar to other examples of oncogenic stimuli-
induced senescence24, TSC2 depletion resulted in increased levels
of the cell cycle inhibitors p21 and p16 (encoded by CDKN2A;
Fig. 1a,b). Similar results were obtained with a different
TSC2-targeting shRNA (Supplementary Fig. 1a). Interestingly,
TSC2-depleted senescent MEFs did not display increased levels of
alternative reading frame (ARF) (also encoded by CDKN2A) or p53
(Fig. 1b), which are critical mediators of oncogenic H-Ras
(H-RasV12)-induced senescence25,26. Also, shTSC2-treated cells
did not show evidence of DNA damage, as indicated by the absence
of phosphorylated histone H2AFX (H2AX) and lack of
Ser15-phosphorylated p53 (Supplementary Fig. 1b, c). These
observations are in agreement with a previous study showing
that mTORC1 hyper-activation via PTEN knockout results in
cellular senescence independently of replicative damage and ARF27.
The cell cycle inhibitor p21 is a main transcriptional target of
p53 and its cellular levels are usually associated with p53 activity.
Despite our lack of evidence of p53 activation by shTSC2, we tested
whether p21 upregulation was mediated by p53. For this, we
silenced endogenous TSC2 in p53-null (p53KO) MEFs by lentiviral
expression of TSC2 shRNAs and p21 upregulation was still clearly
observed despite its lower basal levels (Fig. 1c). Similar results were
obtained with a different TSC2 shRNAs (Supplementary Fig. 1d).
TSC2 knockdown did not induce senescence in p53KO cells
(Supplementary Fig. 1e) probably because p21 levels in these cells
were not sufficiently high. To evaluate the relevance of p21 in
mTORC1-induced senescence, we used p21-null (p21KO) MEFs
and we observed that senescence was notably reduced compared
with wt MEFs (Fig. 1d).
Taken together, these observations indicate that shTSC2-
induced senescence in MEFs depends on p53 and p21. Also, p21
expression is determined by two factors: p53 sustains high basal
levels of p21; and, independently of p53, shTSC2 upregulates p21.
It is important to remark that the upregulation of p21 by
mTORC1 is not secondary to senescence, as exemplified in
p53KO MEFs. We hypothesize that there is a direct mechanistic
link between mTORC1 and p21.
mTORC1 stabilizes p21 protein. Next, we aimed to uncover the
mechanisms responsible for mTORC1-mediated induction of p21.
TSC2 depletion did not significantly upregulate the levels of p21
mRNA in wild-type (WT) and p53KO MEFs (Supplementary
Fig. 2). Therefore, although we cannot exclude a partial
contribution of transcriptional regulation by p53 or by other
factors, post-transcriptional mechanisms must be involved in the
elevation of p21 protein levels upon mTORC1 hyperactivation.
It is well known that mTORC1 preferentially promotes the
translation of a subset of mRNAs characterized by TOP motifs at
the 50-untranslated region (50UTR)10. We could not identify any
obvious TOP motifs in the human or mouse p21 50UTR.
Nonetheless, to unequivocally address the role of translation
initiation, we ectopically expressed mouse p21 in p21KO MEFs
using a plasmid that contained the p21 open reading frame
preceded by a heterologous 50UTR. Importantly, the levels
of ectopically expressed mouse p21 increased upon activation of
mTORC1 by shTSC2 (Fig. 2a). These observations indicate that the
50UTR of p21 mRNA is not required for the effects of mTORC1 on
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p21 protein levels, and suggest that mTORC1 may regulate the
stability of p21 protein. To test this possibility, we analysed the
kinetics of p21 degradation in the presence of the translation
inhibitor cycloheximide. We observed that TSC2 silencing
significantly extended p21 half-life in WT MEFs (Fig. 2b). Also,
the proteasome inhibitor MG132 stabilized the levels of ectopic
mouse p21 (Fig. 2c). Finally, under conditions in which p21
protein does not undergo proteasomal degradation (that is, in
the presence of MG132), p21 levels increased only modestly
upon TSC2 knockdown (Fig. 2d). In conclusion, although we
cannot exclude the participation of other mechanisms, such as
transcription or translation, we conclude that protein stabilization
accounts for most of the upregulation of p21 upon mTORC1
hyperactivation.
Phosphorylation of 4E-BP1 stabilizes p21 protein. Constitutive
activation of mTORC1 is known to shut down the PI3K/AKT
signalling cascade through various negative feed-back loop
mechanisms4 and we confirmed that this is the case in TSC2-
depleted MEFs since phosphorylation of AKT and FOXO
decreased upon TSC2 knockdown (Supplementary Fig. 3a).
We wondered whether the inhibition of PI3K could be involved
in the stabilization of p21. To test this, we treated cells with three
different PI3K chemical inhibitors. All three inhibitors efficiently
blunted AKT phosphorylation, but failed to increase p21 levels,
thus indicating that p21 regulation was not a consequence of
PI3K inhibition (Supplementary Fig. 3b).
Then, we focused on mTORC1 and its proximal downstream
effectors and we obtained a clue from the differential effect of
mTORC1 inhibitors torin-1 and rapamycin on p21 levels28,29.
Torin-1, an ATP-competitive mTOR inhibitor, efficiently inhibited
the phosphorylation of S6 (which reflects S6K activity) and 4E-BP1,
and profoundly decreased p21 levels (Fig. 3a). In contrast,
rapamycin, an mTORC1 allosteric inhibitor, efficiently inhibited
S6 phosphorylation without affecting 4E-BP1 phosphorylation and,
interestingly, the effect on p21 levels was modest (Fig. 3a). In light
of these obervations, we hypothesized that p21 could be a
downstream effector of 4E-BP1. In support of this, a 4E-BP1
phosphorylation-defective mutant (with mTORC1 phosphorylation
sites Thr37, Thr46, Ser65 and Thr70 replaced by alanines,
abbreviated as 4E-BP1-4A) blunted p21 upregulation by shTSC2
(Fig. 3b). Similar results were observed in p53KO MEFs
(Supplementary Fig. 3c) and in p21KO MEFs expressing ectopic
mouse p21 (Supplementary Fig. 3d). Furthermore, mutant
4E-BP1-4A downregulated endogenous p21 in human cancer cell
lines U2OS and HCT116, and also downregulated ectopic human











































































































Figure 1 | mTORC1 activation promotes senescence in MEFs concomitant with p53-independent induction of p21. (a) Representative images illustrating
b-galactosidase activity in MEFs infected with scramble or TSC2 shRNAs (top left panel). Scale bar, 100mm. Average quantification of four (n¼4) independent
experiments±s.d. (bottom left panel). Statistical t-test analysis was performed to calculate significance (***Pr0.005). Western blotting analysis of protein
levels in scramble and TSC2-depleted MEFs (right panel). (b) Western blot depicting changes in protein levels in primary fibroblasts following infection with
TSC2 shRNA, HRasV12 or control viruses. (c) Western blot analysis of protein expression levels in WT MEFs and p53KO MEFs infected with scramble or TSC2
shRNAs lentiviruses. (d) b-Galactosidase activity in WT and p21KO MEFs following infection with scramble or TSC2 shRNAs lentiviruses. Data corresponds to
the average of two (n¼ 2) independent infections±s.d. Statistical t-test analysis was performed to calculate significance (**Pr0.05). For each panel, all the
western blots correspond to samples from the same experiment; in some cases, samples were distributed in several electrophoretic gels run in parallel.
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mutant 4E-BP1-4A decreases the half-life of endogenous p21 in
HCT116 cells (Supplementary Fig. 3e). These observations imply
that phosphorylation of 4E-BP1 by mTORC1 is key for the
stabilization of p21.
Phosphorylation of 4E-BP1 disrupts the complex between 4E-
BP1 and the translation factor eIF4E, releasing free active eIF4E9.
Accordingly, phosphorylation-defective mutant 4E-BP1-4A
associates efficiently to eIF4E (Supplementary Fig. 3f). To test
the involvement of eIF4E in p21 regulation, we used two different
shRNAs that profoundly downregulated eIF4E protein.
Interestingly, inhibition of eIF4E only modestly affected the
basal levels of p21 (Fig. 3d), and failed to prevent the upregulation
of p21 by mTORC1 hyper-activation (Fig. 3e). We conclude that
p21 stabilization by mTORC1 requires the phosphorylation of
4E-BP1 and it is independent of eIF4E.
Non-phosphorylated 4E-BP1 interacts with p21. Having
excluded a role for eIF4E, we wondered whether p21 regulation
could be the result of the interaction between p21 and 4E-BP1.
We envisaged two alternative possibilities: either binding to
phosphorylated 4E-BP1 results in p21 stabilization or binding to
non-phosphorylated 4E-BP1 promotes p21 degradation. We
addressed these possibilities by a series of immunoprecipation
assays, which were all carried out in the presence of the protea-
somal inhibitor MG132 to prevent p21 degradation. Interestingly,
we found that endogenous p21 co-immunoprecipitated with
endogenous 4E-BP1 only in the presence of torin-1, when 4E-BP1
phosphorylation by mTORC1 is completely blunted (Fig. 4a).
Similar results were obtained in human cell lines U2OS and
HCT116 by co-immunoprecipitating endogenous proteins
(Supplementary Fig. 4a), and in 293T cells expressing exogenous
human p21 (Supplementary Fig. 4b). Of note, the mTORC1
inhibitor rapamycin, which failed to reduce phosphorylated 4E-
BP1 efficiently, did not promote the 4E-BP1/p21 interaction
(Supplementary Fig. 4a,b). To directly prove the interaction of
p21 with non-phosphorylated 4E-BP1, we transfected cells with























































































Figure 2 | TSC2 depletion upregulates exogenous p21 levels and increases p21 half-life. (a) Representative western blot showing p21 levels in MEFs co-
infected with pBabe-p21 retrovirus and either control or TSC2 shRNAs retroviruses. (b) Western blot analysis of p21 levels in scramble or TSC2 shRNA-
expressing MEFs following incubation with 10mM cyclohexamide (CHX) for the indicated times (top). Densitometric quantification of p21 levels corrected by
loading control (bottom). (c) Western blot showing exogenous mouse p21 levels in the presence or absence of the proteasomal inhibitor MG132. (d) WT and
p53KO MEFs were infected with either scramble or TSC2 shRNAs lentiviruses. Following selection, the cells were incubated for 8 h in the presence or absence
of the proteasome inhibitor MG132. The p21 immunoblot of p53KO MEFs (right panel) is overexposed compared with WT MEFs (left panel). For each panel,
all the western blots correspond to samples from the same experiment; in some cases, samples were distributed in several electrophoretic gels run in parallel.
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complex formation was readily detected by immunoprecipitation
of either one of the two proteins in 293T cells (Fig. 4b). The
interaction between p21 and 4E-BP1-4A was also demonstrated
in p53-defective HCT116 cells (Supplementary Fig. 4c) and in
TSC2-depleted MEFs (Supplementary Fig. 4d). Interestingly,
eIF4E efficiently bound to endogenous 4E-BP1 and mutant 4E-
BP1-4A, but it did not associate with p21 even in the presence of
4E-BP1-4A (Supplementary Fig. 4e). We conclude that p21 and
eIF4E form separate complexes with non-phosphorylated 4E-
BP1.
To further prove that the 4E-BP1/p21 complex was
independent of eIF4E, we generated an eIF4E-binding-defective
4E-BP1 mutant by substituting residues Leu59 and Met60
of 4E-BP1-4A to Ala30, and this mutant (4E-BP1-4Aþ LM-AA)
was introduced into HCT116 cells under a doxycycline-
inducible promoter. As expected, 4E-BP1-4Aþ LM-AA
double mutant failed to associate to eIF4E (Supplementary
Fig. 4f) but still retained the ability to interact with p21
(Fig. 4c).
Taken together, these results are consistent with a model in
which, under basal conditions, non-phosphorylated 4E-BP1
associates with p21 and promotes its degradation. In contrast,
upon mTORC1 activation, the 4E-BP1/p21 complex is disrupted,




























































































































































































Figure 3 | mTORC1-mediated upregulation of p21 requires 4E-BP1 phosphorylation. (a) Effect of mTOR inhibitors torin-1 (250 nM) and rapamycin
(100 nM) on p21 levels in different cell lines. Cells were treated for 24 h with the indicated drugs and protein levels were subsequently analysed by western
blot. (b) Protein levels in MEFs infected simultaneously with lentiviruses expressing either scramble or TSC2 shRNAs together with control or 4E-BP1-4A.
(c) Protein levels in U2OS, HCT116 and 293T cells transfected with 4E-BP1-4A mutant alone (U2OS and HCT116 cells) or in combination with pBabe-p21
plasmid (293T cells). (d) Western blot depicting protein levels in MEFs following co-infection with lentiviruses expressing the indicated shRNAs. (e)
Primary MEFs were infected with lentiviruses expressing scramble, TSC2 or eIF4E shRNAs in combination with control or 4E-BP1-4A. Protein levels were
measured by immunoblotting. For each panel, all the western blots correspond to samples from the same experiment; in some cases, samples were
distributed in several electrophoretic gels run in parallel.
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p21 expression correlates with mTORC1 activity in HNSCC.
The levels of p21 correlate well with p53 status in most cancer types.
However, this is not the case in HNSCC where p21 levels seem
unrelated to the status of p53 (refs 12–15). On the other hand, the
mTORC1 pathway is frequently hyperactive in HNSCC11,17–22.
These two sets of observations, together with our current
mechanistic findings, made us wonder whether p21 levels could
be governed by the mTORC1 pathway in HNSCC. To test this
hypothesis, we analysed p21, p53 and P-S6 protein levels by
immunohistochemistry (IHC) in a large series (n¼ 274) of
paraffin-embedded tumour samples from surgically treated
HNSCC patients. Of note, to decrease the heterogeneity of the
tumour set, we only studied HPV-negative HNSCC all of them
located in the oropharynx, larynx and hypopharynx
(Supplementary Table 1). Positive p53 immunohistochemical
staining was interpreted as evidence of mutant p53, and positive
P-S6 was used as a surrogate for mTORC1 activity. In agreement
with previous reports12–15, p21 expression showed no association
with p53 functional status in this cohort (Fig. 5a and Supplementary
Table 2). In contrast, a strong positive correlation was found
between p21 and P-S6 (Fig. 5b and Supplementary Table 3). These
observations are consistent with a causal relationship between
mTORC1 activity and p21 levels in HNSCC. To further support
this notion, TSC2 knockdown markedly induced endogenous p21
protein in three different human HNSCC cell lines derived from
primary tumours (Fig. 5c). Moreover, overexpression of a
constitutively active RHEB mutant also increased the levels of
endogenous p21 (Fig. 5d) and ectopic human p21 (Supplementary
Fig. 5a). Finally, TSC2 knockdown increased p21 protein half-life in
UT-SCC-42B cells (Fig. 5e). Taken together, these observations
indicate that the mTORC1/4E-BP1/p21 regulatory axis is active in
HNSCC both in vivo and in vitro. mTORC1-mediated p21
upregulation, did not impact in the phosphorylation status of the
retinoblastoma protein RB1 (Supplementary Fig. 5b), nor resulted
in senescence in HNSCC cell lines (Supplementary Fig. 5c). Since
p53-null MEFs failed to undergo senescence upon mTORC1
hyperactivation (Supplementary Fig. 1e), we wondered if the
HNSCC cells used here could lack functional p53. Indeed, the three
HNSCC cell lines were proven to have deleterious mutations in the
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Figure 4 | p21 interacts with non-phosphorylated 4E-BP1. (a) p21 was immunoprecipitated from WT MEFs untreated of treated with torin-1 (250 nM) for
6 hours in the presence of MG132 (25mM). Inputs and co-inmunoprecipitated proteins were analysed by western blot. (b) 293T cells were transfected with
4E-BP1-4A and flag-p21 plasmids. Cell lysates were immunoprecipitated with either anti-4E-BP1 or anti-flag antibodies following incubation with MG132
(25mM) for 5 h. Inputs and co-immunoprecipitated proteins were analysed by western blot. (c) HCT116-expressing Tet-On-inducible 4E-BP1 mutants were
treated with doxycycline (1 mg ml 1) for 24 h. Cell lysates were immunoprecipitated with anti-p21 antibodies and subjected to immunoblot analysis. (d)
Model for mTORC1/4E-BP1-mediated regulation of p21: Non-phosphorylated 4E-BP1 binds to p21 and promotes p21 degradation. 4E-BP1 phosphorylation
by mTORC1 disrupt the 4E-BP1/p21 complex ensuing p21 accumulation. 4E-BP1 regulates p21 independently of its interaction with the the translation
initiation factor eIF4E. For each panel, all the western blots correspond to samples from the same experiment; in some cases, samples were distributed in
several electrophoretic gels run in parallel.
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determined by us in the case of the UT-SCC-38 and UT-SCC-42B
(Supplementary Fig. 5d). The absence of functional p53 protein was
further confirmed by immunoblot and by the failure of the MDM2
inhibitor nutlin-3 to stabilize p53 (Supplementary Fig. 5e). In
addition to p53 inactivation, other alterations, including CCND1
(cyclin D1) overexpression, or loss of p16, which are common
events in HNSCC11,32, could explain the resistance of these cells to
undergo senescence upon mTORC1 hyperactivation and p21
upregulation. Notwithstanding, p21 upregulation by mTORC1 in
cancer cells may impinge in multiple other cellular processes of
clinical relevance, including apoptosis, differentiation and stem cell
quiescence1,2.
p21 and P-S6 predict survival of HNSCC patients. Next we
examined the impact of both p21 and P-S6 protein expression on
the clinical outcome of HNSCC patients. Interestingly, patients
harbouring tumours positive for either p21 or P-S6 showed a
significantly improved disease-specific survival (Fig. 6a,b).












































































































































































Figure 5 | mTORC1/4E-BP1 regulates p21 expression in HNSCC. (a) Graphical representation of the IHC data to correlate p21 and p53 expression (left)
or p21 and P-S6 expression (S240/244; right; see also Supplementary Tables 2 and 3). Statistical significance was calculated using the Fisher exact test
(two-sided). (b) Representative sections from HNSCC tissue samples depicting the IHC detection of p21 and P-S6 (S240/244). Scale bar, 200mm. (c)
Western blot analysis of p21 and TSC2 protein levels in HNSCC cell lines infected with scramble or TSC2 shRNAs lentiviruses. (d) Western blot analysis of
p21 protein levels in HCT116 cells co-transfected with p21-flag- and Rheb64L-GFP-expressing plasmids. (e) Western blot analysis of p21 levels in scramble
or TSC2 shRNA-expressing UT-SCC-42B cells following incubation with 10mM cyclohexamide (CHX) for the indicated times (left). Densitometric
quantification of p21 levels corrected by the loading control (right). For each panel, all the western blots correspond to samples from the same experiment;
in some cases, samples were distributed in several electrophoretic gels run in parallel.
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expression, the combination of both molecular markers
also associated with a good prognosis (Fig. 6c). However, in
multivariate Cox analysis (including localization of the tumour,
T classification, lymph node metastasis, pathological grade, and
p21þ /P-S6þ phenotype), we found that only the presence of
regional lymph node metastasis at the time of diagnosis was a
significant independent predictor of reduced disease-specific
survival (Supplementary Table 4). Given the dominant prognostic
value of lymph node metastasis, we examined the prognostic
significance of p21þ /P-S6þ phenotype in the subgroup of
patients with no regional lymph node affection at the time of
diagnosis (N0 patients). Indeed, the p21þ /P-S6þ phenotype
strongly associated with improved survival in N0 patients
(Fig. 6d), but not in patients with affected lymph nodes
(Nþ patients; Supplementary Fig. 6). Therefore, hyper-activation
of the mTORC1/4E-BP1/p21 axis could help to predict the
prognosis of HNSCC patients with no lymph node affectation at
the time of diagnosis.
In agreement with previous reports indicating that p21
expression in HNSCC is compatible with proliferation13,14,32,
we did not find a statistical significant correlation between Ki67
staining and p21 expression (Supplementary Table 5) suggesting
that these tumours carry alterations that override the cell cycle
inhibitory activity of p21. Therefore, cell-cycle inhibition is
unlikely responsible for the increased survival rate associated to
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Figure 6 | p21 and P-S6 protein expression correlates with improved survival in HNSCC patients. (a) Kaplan–Meier disease-specific survival curves
categorized by p21. (b) Kaplan–Meier disease-specific survival curves categorized by P-S6 (240/244). (c) Kaplan–Meier disease-specific survival curves
categorized by p21 and P-S6 (240/244). (d) Kaplan–Meier disease-specific survival curves of patients without regional lymph node affection at the time of
diagnosis (N0) categorized by p21 and P-S6 (240/244). (e) Graphical representation of the IHC data to correlate p21þ/P-S6þ -double-positive phenotype
and disease recurrence (left) or distant metastasis (right) (see also Supplementary Tables 6 and 7). For a–d, statistical significance was calculated using the
log-rank test. For e, statistical significance was calculated using the Fisher exact test (two-sided).
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multiple other cellular processes, including apoptosis,
differentiation and stem cell quiescence that could explain the
association of p21 with good clinical prognosis in HNSCC
patients.1,2.
Interestingly, patients with p21/P-S6-double-positive tumours
presented lower rates of recurrence (including local recurrences,
regional recurrences and distant metastasis) and lower incidence
of distant metastases (Fig. 6e and Supplementary Tables 6,7).
A similar trend was observed when the analysis was restricted
to the N0 patients (Supplementary Tables 8, 9). As recurrence
is the main determinant factor for survival, these
observations can explain the improved disease-specific survival
associated to patients with p21/P-S6-double-positive HNSCC
tumours.
Discussion
In this paper, we describe a p53-independent mechanism of
regulation of p21 via the mTORC1 kinase. Our results indicate
that the mTORC1 substrate 4E-BP1 interacts with p21 in its non-
phosphorylated state and promotes p21 destabilization.
Accordingly, mTORC1-mediated phosphorylation of 4E-BP1
abrogates its binding to p21 resulting in p21 stabilization.
Previous studies have reported that p21 levels are affected by
mTORC1 through increased general mRNA translation33 and
specific increased translation of p53 (ref. 27) and p21 (ref. 34)
mRNAs. In addition, activation of mTORC1 inhibits MDM2
through S6K1-mediated phosphorylation35 and nucleolar
sequestration36, leading to p53 activation and p21 upregulation.
Here, we identify another layer of regulation by showing that
mTORC1 can regulate p21 protein levels independently of p53,
eIF4E and the 50UTR sequence of p21 mRNA, via
phosphorylation of 4E-BP1 which disables the destabilization of
p21 by unphosphorylated 4E-BP1.
In primary cells, the upregulation of p21 by mTORC1 results in
senescence only in cells with active p53, but not in cells lacking
p53. The induction of p21-dependent senescence could function
as a barrier to prevent malignant progression of cells with a
hyperactive mTORC1. This protective function, however, is
abrogated in HNSCC probably because they carry multiple
alterations that bypass or cancel senescence, such as inactivation
of p53, overexpression of cyclin D1 or CCNE1 (cyclin E), or loss
of p16, which are all common events in HNSCC11,32.
Nonetheless, p21 is known to regulate a variety of cellular
processes beyond the cell cycle1,2, and these other processes could
be of clinical relevance.
In agreement with previous studies on HNSCC12–15, using a
large series of 274 HNSCC tissue specimens, we found that a
considerable proportion of tumours (67%) showed p21
expression irrespective of p53 status. In contrast, there was a
strong significant correlation between p21 and P-S6 protein
expression, thereby supporting a causal connection between
mTORC1 activity and p21 levels in HNSCC. More importantly,
when correlated with clinical data, we found that p21, P-S6 or the
combination of both proteins significantly associated with
disease-specific survival in our cohort of patients with
orolaryngeal, laryngeal and hypopharyngeal HNSCC. This
association was particularly strong in the case of HNSCC
patients with no lymph node affectation at the time of
diagnosis, which could be of clinical value. In line with our
observations, other types of cancers, such as non-small cell lung
cancer37,38 and luminal breast cancer39, also show a positive
association between hyperactivation of mTOR and good clinical
prognosis. In contrast, a negative association has been reported in
other tumour types, such as oesophageal squamous cell
carcinoma40 and nasopharyngeal carcinoma41.
In summary, our results demonstrate that the mTORC1/
4E-BP1/p21 regulatory axis is relevant in HNSCC, and more
importantly, it favourably affects clinical outcome. These
observations are not in conflict with the oncogenic role of
mTORC1 in these cancers, or with the potential therapeutic value
of mTOR inhibitors for HNSCC. Future studies should uncover
why HNSCC with a hyperactive mTORC1/4E-BP1/p21 pathway
have a better prognosis than tumours with less active mTORC1.
Methods
Cells. Cell lines U2OS (human osteosarcoma), HCT116 (human colon carcinoma)
and were obtained from American Type Culture Collection and were authenticated
after completion of this work. Cell line authentication was performed by analysing
a total of ten microsatellites at the authentication service (Genomic Unit) of
the Institute of Biomedical Research ‘Alberto Sols’ in Madrid. 293T cells were
purchased from Invitrogen. Dr Reidar Grenman provided the HNSCC cell lines
derived from primary lesions: UT-SCC-42B, UT-SCC-2 and UT-SCC-38. These
cells have been previously described42–45. The 4E-BP1/2 KO MEFs were a gift from
Dr Nahum Sonenberg. All cell lines were tested periodically for mycoplasma
contamination using the mycoplasma tissue culture NI (MTC-NI) Rapid Detection
System from GEN-PROBE.
To generate mutant 4E-BP1 inducible cells, HCT116 cells were infected with
lentiviral tet-on plasmid pCW57.1 encoding the 4E-BP1 mutants 4E-BP1-4A and
4E-BP1-4A-LM-AA. The cells were selected with 2 mg ml 1 puromycin for 4 days
and growth in selection thereafter. The expression of 4E-BP1 mutants was induced
by adding 1 mg ml 1 doxycycline to the culture medium for 24–48 h.
All the cell lines were maintained in DMEM supplemented with 10% fetal
bovine serum and antibiotic-antimicotic (all from Gibco), and incubated in 20% O2
and 5% CO2 at 37 C. To grow HNSCC cell lines, the medium was also
supplemented with non-essential amino acids (Sigma).
Reagents. pLESIP 4E-BP1-4A mutant lentiviral plasmid in which Thr37, Thr46,
Ser65 and Thr70 were replaced by Ala was a kind gift from Dr Silvio Gutkind. The
mutant 4E-BP1-4Aþ LM-AA was generated by site-directed mutagenesis using
QuikChange II XL Site-Directed Mutagenesis kit from Agilent Technologies
(#200521). The pCW57.1-4E-BP1-4A Tet-On inducible lentiviral plasmid was
generated in the laboratory of Dr David Sabatini and was obtained from Addgene
(#38240). pBabe-puro-human-p21 was generated in the laboratory of Gordon
Peters and pBabe-puro-mouse-p21 was kindly donated by Mariano Barbacid. The
pMT5-Flag-p21 (human) plasmid was acquired from Addgene (#16240). The
pLJM1-EGFP-Rheb64L plasmid was kindly donated by David Sabatini.
The low-molecular-weight compound CNIO-PI3Ki is covered by patent
WO2010/119264 (files available at the World Intellectual Property Organization,
http://www.wipo.int/pctdb/en/wo.jsp?WO=2010119264). This is a potent inhibitor
of PI3K isoforms p110a (Ki¼ 2.4 nM) and p110d (Ki¼ 9.8 nM; inhibition of the
other PI3K isoforms, p110b and p110g, has values of Ki4100 nM, and inhibition
of a total of 282 additional kinases including mTOR and DNAPK requires
concentrations of IC5041 mM). The small PI3K inhibitor GDC-0941 was obtained
from Shanghai Haoyuan Chemexpress, and LY-294002 was obtained from
CalBiochem. Torin-1 was obtained from Tocris. Rapamycin, nutlin3,
cyclohexamide (CHX) and MG132 (proteasome inhibitor) were obtained from
Sigma. Doxorubicin was purchased to Pharmacia and Upjohn.
Antibodies. The following antibodies were used for western blot and immuno-
precipitation: anti-p16 (M-156) from Santa Cruz, anti-human p53 (DO-1) from
Santa Cruz, anti-p53 (1C12) from Cell Signaling, anti-phospho-p53 (Ser15) from
Cell Signaling (#9284), anti-p19/ARF (5-C3-1) from Santa Cruz, anti-gH2A.X
(Ser139) (clone JBW30) from Millipore, rabbit and goat anti-p21 (C-19) from Santa
Cruz, anti-Tuberin/TSC2 from Cell Signaling (#3612), anti-4E-PB1 (53H11) from
Cell Signaling, anti-phospho-4E-BP1 (37/46) (236B4) from Cell Signaling, anti-
eIF4E (clone #299910) from R&D Systems, anti-phospho-S6 (Ser240/244) from Cell
Signaling (#2215), anti-S6 (5G10) from Cell Signaling, anti-phospho-AKT (Ser473)
(193H12), anti-phospho-AKT (Thr308) from Cell Signaling (#9275), anti-AKT from
Millipore (07-416), anti-phospho-FOXO1(T24)/3a(T32), anti-FOXO1 (C29H4)
from Cell Signaling, anti-flag M2 from Agilent anti-phospho-RB1 (Ser807/811)
(D20B12) from Cell Signaling (#8516), anti-RHEB (C-19) from Santa Cruz.
For IHC, the following antibodies were used: rabbit monoclonal Phospho-S6
Ribosomal Protein (Ser240/244; D68F8 XP; Cell Signaling # 5364) at 1:200 dilution;
Novocastra Liquid mouse monoclonal antibody p21WAF1 Protein (Clone 4D10;
Leica Biosystems NCL-L-WAF-1) at 1:10 dilution; mouse monoclonal anti-human
p53 Protein (Clone DO-7; Dako # M 7001) and Ki67 (Dako, clon MIB-1,
prediluted).
Senescence assay. MEFs were infected with scramble or TSC2 shRNA lentivirus
and selected with puromycin for 4 days. 10–14 days after infection, b-galactosidase
activity was assessed with a b-Galactosidase Staining Kit (Cell Signaling #9860). In
each experiment, b-Galactosidase-positive and -negative cells were counted in at
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least ten different fields. Statistical significance was analysed by a Student’s two-side
t-test. Data represent the mean±s.d. of independent experiments.
RNA interference. Silencing of endogenous proteins was performed using
pLKO.1 lentiviral plasmids encoding specific shRNA sequences. All the lentiviral
shRNA plasmids were purchased from Sigma: mouse TSC2-1 shRNA
(TRCN0000042723), mouse TSC2-1 shRNA (TRCN0000042724), human TSC2
shRNA (TRCN0000040178), mouse eIF4E-1 shRNA (TRCN0000077475), mouse
eIF4E-2 shRNA (TRCN0000077477). Control plasmid pLKO.1 scramble shRNA
was acquired from Addgene (plasmid 1864). Infective lentiviral particles were
produced according to the manufacturer’s instructions. Briefly, HEK293FT cells
(Invitrogen) were co-transfected with shRNA vectors and the lentivirus packaging
plasmids PLP1, PLP2 and PLP-VSVG. The lentiviral supernatants were collected
48 h after transfection, filtered and used to infect the cell lines of interest. Following
infection, the cells were selected for 3–4 days with 2 mg ml 1 puromycin.
Protein analyses. The western blotting procedure has been previously described46.
Primary antibodies (at a 1:1,000 dilution) were detected with secondary antibodies
labelled with Alexa Fluor 680 (Molecular Probes; at a 1:5,000 dilution) and were
visualized using a LI-COR Odyssey scanner. When Trueblot horseradish
peroxidase-conjugated secondary antibodies (Rockland) were used (at a 1:1,000
dilution), chemiluminescence was detected with a Molecular Imager Gel Doc XR
System (Bio-Rad). Proteins with similar or identical molecular weight (for example,
phosphorylated and non-phosphorylated) were blotted in independent and
equivalent gels. For protein half-life assays, cells were treated with 10 mM CHX
during the indicated times.
For immunoprecipitation, cells were treated with 20 mM MG132 for 4–6 h
and then lysed in lysis buffer (50 mM Tris pH8, 1 mM EDTA, 120 mM NaCl and
1% NP40) containing phosphatase inhibitors (0.25 mM Na3VO4, 10 mM NaF,
1 mM phenylmethylsulphonyl fluoride) and supplemented with a protease
inhibitor cocktail (Roche). Cell lysates (2–4 mg) were incubated with the
immunoprecipitating antibody (1 mg) along with either Trueblot anti-rabbit IgG IP
beads (Rockland) or protein-G Sepharose beads (GE Helthcare) at 4 C overnight.
Beads were washed four times with lysis buffer, resuspended in 2 Laemmli
sample buffer and resolved by western blotting. For immunoprecipitation, the
following antibodies were used: goat anti-p21 antibody (C-19 Santa Cruz), rabbit
anti-4E-BP1 (53H11, Cell Signaling) and rabbit anti-eIF4E antibody (clone
#299910, R&D Systems). To prevent hindrance by the immunoprecipitated IgG
light-chain proteins, IgG Trueblot secondary antibodies (Rockland) were used. In
addition, as p21 and 4E-BP1 proteins exhibit similar molecular weights and in
order to avoid interference of both signals, these co-immunoprecipitated proteins
were resolved in two independent western blots. Uncropped images of all the
inmunoblots can be found in Supplementary Note 1.
Quantitative real-time PCR. Total RNA was isolated with Trizol reagent
(Invitrogen). cDNA synthesis was performed with 5 mg total RNA using
Ready-To-Go You-Prime First-Strand Beads (GE Healthcare). Quantitative
real-time PCR was carried out with SybrGreen Master Mix (Applied Byosystems)
in a 7500 Fast Real-Time PCR System (Applied Byosystems). Reactions were
performed in triplicate and normalized by b-acting expression. Primer sequences
are depicted below:
CDKN1A forward: 50-GTGGGTCTGACTCCAGCCC-30 ;
CDKN1A reverse: 50-CCTTCTCGTGAGACGCTTAC-30 ;
b-actin forward: 50-GGCACCACACCTTCTACAATG-30 ;
b-actin reverse: 50-GTGGTGGTGAAGCTGTAGCC-30 .
Patients and tissue specimens. Surgical tissue specimens from 274 patients with
HNSCC who underwent resection of their tumours at the ‘Hospital Universitario
Central de Asturias’ between 2000 and 2009 were collected, in accordance to
approved institutional review board guidelines. All experimental protocols were
approved by the Institutional Ethics Committee of the Hospital Universitario
Central de Asturias and by the Regional CEIC from Principado de Asturias for the
project PI13/00259. Written informed consent was obtained from all patients.
Representative tissue sections were obtained from archival paraffin-embedded
blocks and an experienced pathologist confirmed the histological diagnosis. All
patients had a single primary tumour, microscopically clear surgical margins and
received no treatment before surgery. Only 12 patients were women, and the mean
age was 59 years (range 36–86 years; see Supplementary Table 1). All but 10
patients were habitual tobacco smokers, 164 moderate (1–50 pack-year) and 100
heavy (450 pack-year), and 241 were alcohol drinkers. The stage of the tumours
was classified according to 7th edition of the Tumour-nodes-metastasis system of
the Union for International Cancer Control: 18 tumours were stage I, 14 were stage
II, 42 were stage III and 200 were stage IV. According to Broders’ classification, the
series included 100 well, 110 moderately and 64 poorly differentiated tumours.
None of the patients presented distant metastasis at the time of diagnosis. After
surgery, and in function of the tumour stage, 164 (60%) patients received post-
operative radiotherapy. HPV status was available for the whole series47,48. To
improve sample uniformity, all HPV-positive cases (n¼ 10) were excluded from
the analysis.
Tissue arrays. Morphologically representative areas were selected from each
individual tumour paraffin block: three 1 mm cylinders were taken to construct
tissue array blocks as described previously49 containing a total of 274 HNSCC (141
oropharyngeal, 65 hypopharyngeal, 68 laryngeal carcinomas). Briefly, the original
archived haematoxylin-and-eosin-stained slides were reviewed by a pathologist and
1 mm diameter tissue cores from donor blocks were transferred to a recipient
‘Master’ block in a grid-like manner using a manual tissue array instrument. Three
tissue cores were taken from the donor tissue blocks to fully represent each case. In
addition, each tissue array included three cores of normal epithelium as an internal
negative control. To check the histopathological diagnosis and the adequacy of
tissue sampling, a section from each tissue array was stained with haematoxylin
and eosin and examined using light microscopy.
Immunohistochemistry. The formalin-fixed, paraffin-embedded tissues HNSCC
TMAs were cut into 3-mm sections and dried on Flex IHC microscope slides
(Dako). The sections were de-paraffinized with standard xylene and hydrated
through graded alcohols into water. Antigen retrieval was performed using
Envision Flex Target Retrieval solution, high pH (Dako). Staining was done at
room temperature on an automatic staining workstation (Dako Autostainer Plus)
using the Dako EnVision FlexþVisualization System (Dako Autostainer) and the
antibodies previously described. Immunostaining was scored blinded to clinical
data by two independent observers. Staining data were dichotomized as negative
expression (0–10% stained cells) versus positive expression (410% stained cells).
Genomic p53 sequencing. Primers and protocols used to sequence genomic p53
from HNSCC cell lines were found at the IARC TP53 Database: http://p53.iarc.fr.
Statistical analysis. Survival curves were analyzed using the Kaplan–Meier pro-
duct limit estimate. Differences between survival times were analysed by the log-
rank method. Fisher’s test was used to analyse two-by-two tables. For continuous
variables, we used the Student’s t test. Cox proportional hazard models were used
to examine the relative impact of those statistically significant variables in uni-
variate analysis. P values of r0.05 were considered to be statistically significant.
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